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Genetically engineered red cells expressing single
domain camelid antibodies confer long-term
protection against botulinum neurotoxin
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A short half-life in the circulation limits the application of therapeutics such as single-domain
antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs.
Here we present VHHs against botulinum neurotoxin A (BoNT/A) on the surface of red
blood cells by expressing chimeric proteins of VHHs with Glycophorin A or Kell. Mice whose
red blood cells carry the chimeric proteins exhibit resistance to 10,000 times the lethal dose
(LD50) of BoNT/A, and transfusion of these red blood cells into naive mice affords protection
for up to 28 days. We further utilize an improved CD34+ culture system to engineer human
red blood cells that express these chimeric proteins. Mice transfused with these red blood
cells are resistant to highly lethal doses of BoNT/A. We demonstrate that engineered red
blood cells expressing VHHs can provide prolonged prophylactic protection against bacterial
toxins without inducing inhibitory immune responses and illustrates the potentially broad
translatability of our strategy for therapeutic applications.
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VHHs are single-domain antibodies of molecular weight~15 kD that are derived from the unusual heavy-chain-only antibodies produced by camelids1. Compared to
conventional antibodies, VHHs are more stable and are typically
better expressed in recombinant hosts. They also have a greater
tendency to recognize conformational shapes (reviewed in ref. 2).
While single VHHs can be potent toxin-neutralizing agents,
greatly improved therapeutic efﬁcacy has been demonstrated
in several animal models when two or more different toxin-
neutralizing VHHs were linked and expressed as multi-speciﬁc
VHH-based neutralizing agents (VNAs)3–7. Though VNAs are
highly effective antitoxins in vivo, their half-life in circulation is
relatively short8, and it is thus important to improve the
serum half-life of VNAs to substantially increase the duration of
antitoxin protection.
We chose to use botulinum neurotoxin serotype A (BoNT/A)
as our model toxin due to its importance as both a source of food
poisoning and a potential bioweapon and the robust tools
available for evaluating and quantifying antitoxin therapeutic
efﬁcacy. BoNT/A targets neurons and inhibits the release
of neurotransmitters from presynaptic terminals by cleaving
synaptosomal-associated protein of 25 kDa (SNAP25), a member
of the soluble N-ethylmaleimide-sensitive factor-attachment
protein receptor protein family9. Blocking neurotransmitter
release at the neuromuscular junction leads to ﬂaccid paralysis
and death10. Because of its extreme potency and wide availability,
BoNT/A is considered a category A bioweapon by the Centers
for Diseases Control and Prevention10. We have previously
reported development and testing of potent antitoxin VNAs
for treating BoNT/A botulism7, 11. We also showed that
appending an albumin-binding peptide to the C’-terminus of
VHH anti-botulinum increases the serum half-life of this VHH to
1–2 days11. Other groups have also administered a combination
of biotinylated VHH anti-BoNT/A and a fusion protein consist-
ing of a scFv-speciﬁc to murine glycophorin A (GPA) and
streptavidin. This strategy increases the VHH retention time in
the circulation as well as its neutralization potency in mice.
Nevertheless, neutralization protection only lasts for a maximum
of 4 days, indicating the short-lived stability of the complex12.
Aiming to improve the half-life of VHHs and VNAs in
the circulation in vivo, we covalently linked these agents to
proteins on the surface of red blood cells (RBCs), the most
abundant cell type in the human body. Because RBCs have a
circulatory half-life of 120 days in humans and ~30–50 days in
mice, attached cargoes can potentially circulate for weeks unless
modiﬁed RBCs are cleared more rapidly. RBCs also possess
a natural biocompatibility and a large surface area, allowing
covalent attachment of large numbers of cargoes without
provoking adverse immune reactions13–15. Indeed, RBC transfu-
sion has been carried out for centuries with negligible side effects.
Lastly, RBCs lack nuclei, eliminating risks associated with
administration of nucleated cells, especially those previously
subjected to genetic manipulation14, 16.
Several techniques have been developed to attach therapeutic
cargoes to the surface of RBCs17. Covalent chemical attachment
provides strong cargo binding but chemical medication methods
are not speciﬁc and may alter membrane properties and blood
antigens18, 19. Antibody-mediated binding to RBCs has also
been employed, though cargo dissociate over time20. To preserve
the native biological properties of RBCs and to seek to prolong
the circulation time of VHHs, we developed a different strategy
in which we generated virus vectors encoding chimeric proteins
with one or more VHHs fused in frame to a cDNA encoding
the RBC membrane proteins GPA or Kell. By expressing these
cDNAs in murine RBC progenitors and generating RBCs
either by in vitro culture or stem cell transplantation, we show
that the half-life of anti-BoNT VHHs can be extended to several
weeks, equal to that of unmodiﬁed RBCs. These anti-BoNT
VHHs are functional; they bind, neutralize, and remove BoNT/A
from the circulation. Mice transfused with engineered RBCs
accounting for <1% of total RBCs are resistant to multiple lethal
doses of BoNT. Finally, we demonstrate that human RBCs can
be produced in culture and engineered to express chimeric
proteins containing anti-BoNT VHHs. Transfusion of these
engineered RBCs into mice protects them from death caused by
BoNT challenge. We suggest that similar types of engineered
human RBCs can be used to provide long-term protection
against exposures to a variety of bacterial toxins and harmful
viruses.
Results
In vitro characterization of engineered mouse reticulocytes.
We ﬁrst generated retroviral constructs that can infect red cell
progenitors and lead to expression of chimeric proteins on the
surface of mature RBCs. We chose GPA and Kell as the RBC
membrane protein targets and genetically fused antitoxin VHHs
at the N’-terminus of GPA and at the C’-terminus of Kell,
respectively, to expose the VHHs on the external surface of
the RBC plasma membrane (Fig. 1a). Both BoNT serotype A
(BoNT/A) and serotype B (BoNT/B) are extremely toxic to
humans; the two bispeciﬁc VNAs, termed VNA/A and VNA/B,
recognize and neutralize BoNT/A and BoNT/B, respectively.
VNA/A and VNA/B are heterodimers of two linked VHHs that
recognize different epitopes on BoNT/A (ciA-H7 and ciA-B5)3 or
BoNT/B (JLU-D10 and JLI-G10, unpublished). The two VHHs
are separated by a (GGGGS)3 ﬂexible spacer, and a myc-tag was
added to the N′-terminus of GPA-VNA and the C′-terminus of
Kell-VNA to simplify analysis. We infected E14.5 mouse fetal
liver red cell progenitors with these retroviruses as well as with an
empty vector as control. The progenitors were then cultured
in vitro to differentiate into reticulocytes. Terminally differ-
entiated cells express the chimeric GPA or Kell proteins on their
surface, as indicated by myc surface expression (Supplementary
Fig. 1a). Each RBC was estimated to express ~4,600,000 copies of
GPA-VNA and 2,200,000 copies of Kell-VNA proteins per
cell (Supplementary Fig. 1b; see Methods section and legend
to Supplementary Fig. 1b for calculation). In this in vitro mouse
fetal liver culture system, the VNA-expressing cells undergo
enucleation at a level similar to control cells and have similar
CD71 and Ter119 surface expression, proliferation, and
morphology compared to control cells, suggesting that these
modiﬁcations do not disturb normal red cell differentiation
(Supplementary Figs. 1c–f).
We evaluated the ability of these engineered RBCs to neutralize
BoNT/A using in vitro neutralization assays (Fig. 1b). Primary
rat neurons were co-incubated with BoNT/A and various
amounts of engineered RBCs. More than 70% of SNAP25 was
cleaved in control cultures, while SNAP25 was mostly intact
in neurons co-incubated with 1,000,000 or 100,000 GPA-VNA/A-
expressing RBCs. Incubation with 1,000,000 or 100,000 Kell-
VNA/A-expressing cells also protected neurons from BoNT/A.
The protective ability of the GPA-VNA/A and Kell-VNA/A was
speciﬁc since there was no protection conferred by RBCs with
surface expressed VNA/B.
Engineered mouse RBCs protect against BoNT/A in vivo. Since
our engineered RBC progenitors undergo normal erythropoiesis
in vitro, we next produced engineered RBCs in vivo by
transplanting irradiated mice with fetal liver red cell progenitors
engineered to express GPA-VNA/A or Kell-VNA/A. Complete
blood counts (CBCs) and myc surface expression (indicating the
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Fig. 1 Genetically engineered murine RBCs covalently linked to VHHs against BoNT/A protect neurons in vitro and mice in vivo against BoNT/A challenge.
a Design of the chimeric proteins. Each chimera was assembled from different protein segments shown as colored boxes (yellow: signal peptide of GPA;
red: myc epitope; VHH-H7 and VHH-B5: anti-BoNT/A VHHs; grey: spacer; VHH-D10 and VHH-G10: anti-BoNT/B VHHs; GPA human glycophorin A).
b RBC potency to neutralize BoNT/A assessed by SNAP25 immunoblot following overnight treatments of primary rat neurons exposed to 20 pM BoNT/A
preincubated with the indicated number of myc+ RBCs. The percentage of SNAP25 cleaved by BoNT/A was estimated by image analysis. Left: RBCs
expressing either GPA-VNA/A or Kell-VNA/A; Right: RBCs expressing GPA-VNA/B or Kell-VNA/B. c Complete blood counts of control 7-week-old female
C57BL/6J mice and mice subjected to bone marrow transplantation with progenitor cells expressing vector or GPA-VNA/A and bled at the indicated time
points. (n= 4/group, mean± S.E.M.). d Myc surface expression on red cells from GPA-VNA/A transplanted mice was measured by ﬂow cytometry at the
indicated time points; the percentage of myc+ cells was determined. (n= 4/group, mean± S.E.M.). e Kaplan–Meier survival plots of mice challenged with
BoNT/A. CD1 mice were subjected to bone marrow transplantation with progenitor cells expressing GPA-VNA/A or Kell-VNA/A. After bone marrow
reconstitution, these mice were challenged with 10 LD50 BoNT/A and monitored for a week. The surviving mice received increasing doses of BoNT/A in
subsequent weeks. The mice bearing Kell-VNA/A RBCs were challenged up to 3 weeks before protection faltered, whereas the mice carrying GPA-VNA/A
were challenged for up to 6 weeks with increasing doses as indicated and were still alive at the termination of the study (n= 5/group). All mice with RBCs
expressing GPA-VNA/A survived following the ﬁnal 10,000 LD50 treatment without showing signs of botulism
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expression of the GPA-VNA/A chimera) from one batch of
GPA-VNA/A-transplanted mice was followed over time
(Fig. 1c, d). Compared to 7-week-old female mice, the blood
parameters of the transplanted mice varied but were still within
the normal range reported in the Mouse Phenome Database on
the Jackson Laboratory website. Moreover, the average myc sur-
face expression was stable over 6 months. In a separate batch of
mice transplanted with cells expressing GPA-VNA/A, 2.96±
0.10% of the RBCs were myc+, and mice transplanted with cells
expressing the Kell-VNA/A chimera had 14.26± 0.25% myc+
RBCs after 6 week bone marrow reconstitution (±S.E.M.; n= 5).
As shown in Supplementary Fig. 1g, each of these RBCs con-
tained about 310,000 GPA-VNA/A proteins per cell, about 1/15th
that found on red cells made in our in vitro culture.
These mice were then challenged with BoNT/A. As shown in
Fig. 1e, both GPA-VNA/A- and Kell-VNA/A-producing mice,
but not wild-type mice, survived a 10 LD50 BoNT/A challenge.
Seven days later, we challenged these surviving mice with a 100
LD50 of BoNT/A; both GPA-VNA/A and Kell-VNA/A mice
survived. We then kept challenging the mice at weekly intervals
with higher doses of BoNT/A. The Kell-VNA/A-expressing mice
died at 250 LD50; remarkably, the GPA-VNA/A mice survived
even when challenged with 10,000 LD50 BoNT/A.
The protective capacity of the engineered RBCs is
versatile, since 60% of mice with 4.77± 1.18% (±S.E.M.; n= 5)
GPA-VNA/B-expressing RBCs survived a BoNT/B challenge as
high as 1,000 LD50 (Supplementary Fig. 2) and 100% of
mice expressing the GPA-VNA/B chimera survived a 100 LD50
BoNT/B challenge.
Since red cells expressing the GPA-VNA/A chimeras seem to
provide more potent protection in vivo than do Kell-VNA/A
mice, we carried out our subsequent experiments utilizing GPA as
the RBC membrane anchor proteins for our chimeric proteins.
It is likely that this potent protection stems from the
continuous replenishment of engineered RBCs by the bone
marrow of the reconstituted mice. Transfusion of engineered
RBCs is a more realistic option to exploit engineered RBCs
therapeutically in humans. Therefore, we transfused wild-type
mice with 100 μl of blood drawn from chimeric mice in
which 6.22± 0.25% of the RBCs displayed surface GPA-VNA/A
(±S.E.M.; n= 5). As there are 107 cells/μl of whole blood, we
therefore injected 6.22 × 107 GPA-VNA/A-expressing RBCs. We
then challenged the recipient mice with BoNT/A (Fig. 2a). Blood
containing GPA-VNA/A RBCs protected mice from 10 LD50
BoNT/A, although these mice died within 24 h if challenged with
≥100 LD50 doses of BoNT/A. We reasoned that there were not
enough cells to neutralize the higher doses of BoNT/A at the site
where the toxins enter the circulation. We thus injected 400 µl of
blood from the transplanted GPA-VNA/A chimeric mice into
other recipients and found that these mice were protected from
100 LD50 BoNT/A challenge (Fig. 2b).
Several reports showed that the half-life of VHHs in vivo is
very short21 and unmodiﬁed anti-BoNT/A VNAs protect mice
from BoNT/A challenge for less than a day postadministration11.
The half-life of an antibody can be prolonged, as shown in
a human study that humanized monoclonal anti-BoNT/A
antibodies had half-lives varying from 2.5 to 26.9 days depending
on the dose of antibody administrated22. Here we analyzed the
half-life of the transfused engineered RBCs in the circulation. To
this end, we stained the RBCs with a violet-trace dye prior to
transfusion to monitor the total population of transfused RBCs
and tracked cells expressing VNAs by green ﬂuorescent protein
(GFP) signal (from a GFP expression cassette in the lentivirus
vector) (Fig. 2c). The half-life of control, GPA-VNA/A, and
Kell-VNA/A RBCs were all approximately 14 days, similar to
that of normal mouse RBCs. We then challenged these mice with
10 LD50 BoNT/A at different times after transfusion and found
that the antitoxin-protective capacity of the engineered RBCs
lasted up to 28 days (Fig. 2d). Taken together, our work
demonstrated that covalently conjugating VNAs onto RBCs
allows a dramatic extension of the circulatory half-life of the
VNAs without compromising their neutralizing capacity.
Engineered RBCs pose no detrimental side effects in vivo. To
determine the fate of BoNT/A and the engineered RBCs in mice,
we incubated violet-dyed wild-type RBCs or GPA-VNA/A-
expressing RBCs with catalytically inactive BoNT/A (ciBoNT/A)
before transfusing the mixture into mice. We bled the recipient
mice at intervals and analyzed amounts of both free (Fig. 3a) and
RBC-bound ciBoNT/A (Fig. 3b) in the serum. As shown
in Figs. 3a, 1 h after injection (“0 day” on the graph) there is
very little free ciBoNT/A in the serum of mice transfused with
GPA-VNA/A-expressing RBCs, compared to mice transfused
with control RBCs. In contrast, ~100 times more RBCs appear to
have bound ciBoNT/A in mice transfused with GPA-VNA/A-
expressing RBCs than in mice transfused with control blood
based on the RBC surface S-tag signal (from the anti-ciBoNT/A
probe; Fig. 3b). RBC-bound ciBoNT/A is cleared from
serum after 7 days (Fig. 3b), approximately concurrent with the
GPA-VNA/A (GFP+ cells) (Fig. 3c). Since the GPA-VNA/A-
expressing cells (GFP+ cells) were cleared signiﬁcantly faster than
the other RBCs (Fig. 3c) and similar to bound ciBoNT/A
(Fig. 3b), a high percentage of GPA-VNA/A RBCs must
have become bound to ciBoNT/A. We hypothesize that binding
of BoNT/A to GPA-VNA/A-expressing RBCs enhances
their degradation by macrophages or dendritic cells in the spleen
or liver23–25.
We performed the same experiment but bleeding intervals were
taken within 1 h after transfusion. Transfused GPA-VNA/A
RBCs still bound ~100 times more ciBoNT/A than control RBCs,
despite the ~20% loss of bound ciBoNT/A from the GPA-VNA/A
RBCs at 1 h compared to 5 min (Supplementary Fig. 3). Since
undetectable numbers of transfused cells were lost between 5 min
and 1 h, it was appropriate to use 1 h as “time 0” in the
experiment in Fig. 3a–c.
Multiple repeat antibody administration typically elicits
an adverse immune response. We therefore investigated the
immune response in mice after three injections of control RBCs,
GPA-VNA/A RBCs, or equimolar amounts of recombinant
VNA/A (Fig. 3d). We used enzyme-linked immunosorbent assay
(ELISA) to detect the relative abundance of anti-VNA/A
antibodies in the serum. At 1:333 and 1:111 serum dilutions,
very little antibody was detected in mice receiving control or
GPA-VNA/A RBCs, whereas large amounts of anti-VNA/A
antibody were detected following injection of the VNA protein.
As shown by the ELISA performed at a 1:37 serum dilution, the
amount of anti-VNA produced against the VNA-expressing red
cells is at least 10-fold less than that from VNA/A-injected mice.
Heterodimeric VHHs protect more robustly than monomeric
VHHs. Given that murine RBCs expressing the GPA-VNA/A
chimera are very potent, we also examined whether monomeric
VHHs can be used instead of bispeciﬁc VNAs. Thus we
constructed another plasmid (GPA-VHH7) to generate a
chimeric protein fusing ciA-H7 VHH with GPA (Fig. 4a). We
then produced cultured mouse RBCs expressing GPA-VNA/A
and GPA-VHH7 and showed that they express similar levels of
chimeric GPA and have similar BoNT/A-neutralizing potency
in neuronal cell-based assays (Fig. 4b). Mice transfused
with an equivalent amount of cultured RBCs expressing either
GPA-VNA/A or GPA-VHH7 were protected from 25 LD50 of
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Fig. 2Mice transfused with engineered RBCs are protected against BoNT/A challenges. a C57BL/6J mice were transfused with 100 μl blood from chimeric
mice previously transplanted with GPA-VNA/A-expressing progenitors. The recipient mice were challenged with 10, 100, or 1000 LD50 BoNT/A 2 h later
and survival was monitored (n= 6/group). Note: the curves depicting control mice and transfused mice challenged with 100 and 1,000 LD50 are
overlapping. b C57BL/6J mice transfused with 400 μl blood from chimeric mice previously transplanted with GPA-VNA/A-expressing progenitors were
challenged with 100 LD50 BoNT/A 1 h after transfusion and survival was monitored (n= 4/group). c Circulatory half-life of the transfused RBCs. In all, 100
µl of blood from transplanted mice with ~3% of their RBCs expressing vector only, GPA-VNA/A, or Kell-VNA/A were stained with violet-trace dye and
transfused into recipient mice. The fraction of transfused RBCs in recipients was analyzed by ﬂow cytometry at the indicated time points. The violet-trace
dye represents the total population of transfused red blood cells, of which only ~3% are GFP+ and express the exogenous chimeric protein, while the
GFP signal represents only the 3% of the transfused RBCs expressing the VNAs. (n= 3/group, mean± S.E.M.). d Survival plot of transfusion recipient
mice treated as in the diagram were challenged with 10 LD50 BoNT/A at 1 h, 4 days, 14 days and 28 days post-transfusion and monitored for 7 days
(n= 6/group)
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BoNT/A (Fig. 4c) while only the GPA-VNA/A mice were
protected from 50 LD50, and to a lesser extent at even higher
doses. The results suggest that there may be a small potency
advantage in vivo when using RBCs displaying bispeciﬁc VNAs
vs. monospeciﬁc VHHs.
Engineered human reticulocytes expressing heterodimeric
VHHs. Finally, we explored the possibility of producing
engineered human RBCs from human CD34+ progenitor cells.
We modiﬁed our current CD34+ cell culture protocol and
measured the cell number, differentiation markers, membrane
proteins, and enucleation at the end of each developmental stage.
As shown in Table 1, we developed a six-stage culture system, a
modiﬁcation of the four-stage system used previously in
our laboratory and the three-stage system used by other labora-
tories26, 27. In our modiﬁed system, mobilized bone marrow
CD34+ stem/ progenitor cells expanded >300,000-fold during the
23-day culture period (Fig. 5a). Differentiation was gradual and
synchronous; as an example, c-kit expression was initially high
and declined with differentiation, whereas CD71 and CD235A
expression increased. At the time when CD71 (transferrin
receptor) expression began to decrease, cells began to enucleate;
>90% of cells had undergone enucleation and became reticulo-
cytes by the end of the culture (Fig. 5b). The enucleated cells are
7 µm in diameter, similar to human reticulocytes28, and contain
28.23± 0.46 pg hemoglobin/cell (n= 3) within the normal range
for human RBCs (Fig. 5c)29. We also monitored the survival of
these in vitro-differentiated human reticulocytes in vivo and
found that they can circulate for at least 7 days in macrophage-
depleted nonobese diabetes/severe combined immunodeﬁciency
(NOD/SCID) mice (Fig. 5d). About 94% of cultured reticulocytes
survived in these mice at 1 day post-transfusion and ~36% cells at
3 days, comparable to the recent published data30. Overall, we
improved the system in terms of the number of differentiated,
enucleated cells (93.53± 2.84% enucleation; n= 3). We compared
the expression of multiple surface proteins at the end of each
culture stage and showed that the expression pattern of these
proteins is similar to that previously reported31. As examples,
GPA (CD235A) and Rhesus (CD240DCE) increase over time,
and CD36, CD47, CD59, CD71, CD147, α4 integrin (CD49d), α5
integrin (CD49e), β1 integrin (CD29), and Kell show decreased
expression during differentiation (Fig. 6a).
We then infected CD34+ stem/progenitor cells with lentiviral
vectors that express the hGPA-VNA/A or hKell-VNA/A chimeric
proteins depicted in Fig. 1a. Importantly, control and GPA-VNA/
A-expressing cells show similar expression patterns of multiple
surface proteins, suggesting that expression of this chimeric
protein does not signiﬁcantly alter differentiation (Fig. 6a).
Western blotting analysis showed that our six-stage cultured
control or GPA-VNA/A-expressing reticulocytes contain similar
amounts of GPA, Kell, β1-integrin, band 3, and XK proteins,
compared to human RBCs (Supplementary Fig. 4b). Moreover,
the morphology of vector control and GPA-VNA/A-expressing
CD34+ cells are similar to uninfected CD34+ cells at each stage,
indicating that the cells differentiate properly (Fig. 6b). However,
infection of CD34+ cells leads to a reduced number of cells
undergoing enucleation (to ~70–80%; Fig. 6b). The growth rate is
unperturbed following the expression of GPA-VNA/A (Fig. 6c).
Enucleated cells express ~500,000 copies of hGPA-VNA/A or
120,000 copies of Kell-VNA/A, as indicated by myc expression
(Supplementary Fig. 4a, see legend for calculation). The number
of chimeric proteins in engineered human cells is lower than that
in engineered mouse cells, which could result from varying
numbers of viral particles infecting cells and from the use of
different vectors with different promoters.
Engineered human reticulocytes protect against BoNT/A. We
co-incubated these engineered human RBCs with neurons in the
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Fig. 3 No detrimental side effects in mice injected with engineered RBCs.
a Detection of serum persistence of unbound ciBoNT/A in the circulation. In
all, 2 ng ciBoNT/A was incubated with 200 μl violet-stained RBCs
expressing the control vector or GPA-VNA/A before they were transfused
into recipient mice. The sera was collected at intervals and the amount of
unbound ciBoNT/A in the serum was measured by ELISA (n= 3/group,
mean± S.E.M.). b, c Detection of RBC-bound ciBoNT/A and transfused
RBCs in the blood of recipient mice. In all, 200 μl blood from wild-type mice
and from mice transplanted with GPA-VNA/A expressing RBCs was stained
with violet-trace dye and incubated with 1 μg ciBoNT/A before transfusion
into mice. Recipients were bled at the indicated time points. RBCs were
subjected to ﬂow cytometric analyses to quantify the violet trace (total
transfused RBCs, panel c), GFP (virus-transduced cells, b), and S-tag
(indirectly detecting RBC-bound ciBoNT/A, panel b) (n= 3/group, mean±
S.E.M.). In Fig. 2c, the GPA-VNA/A RBCs measures total RBCs from GPA-
VNA/A chimera mice, which are a combination of non-transduced (~97%)
and transduced cells (~3%). To further distinguish the transduced cells, we
gated on the GFP+ (GPA-VNA/A) RBCs and GFP− populations (control
RBCs). The difference between the GFP+ and GFP− curves is statistically
signiﬁcant by ANOVA two-tailed analysis. d As detailed in the Methods
section, mice received three injections of control blood, GPA-VNA/A blood,
or VNA/A protein, and relative abundance of antibody against-VNA/A in
serum from these mice was examined by ELISA. Sera were diluted at the
indicated ratios (n= 5/group, mean + S.E.M.)
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presence of BoNT/A. Co-incubation with one million hGPA-VNA/
A or hKell-VNA/A-expressing human RBCs partially inhibited
BoNT/A activity and ﬁve million hGPA-VNA/A-expressing human
RBCs fully prevented SNAP25 cleavage (Fig. 6d). Our in vitro-
cultured human reticulocytes survive following transfusion in
NOD/SCID mice for at least 7 days (Fig. 5d) and this ability allowed
us to examine the protective capacity of the engineered human
RBCs in vivo. Furthermore, the percentage of surviving, circulating
reticulocytes expressing vectors or GPA-VNA/A, as well as mature
human RBCs, in NOD/SCID mice is similar from 5min post-
transfusion to 1 h (Supplementary Fig. 4c). We therefore transfused
150,000,000 hGPA-VNA/A-expressing human reticulocytes into
NOD/SCID mice and challenged them with 10 LD50 of BoNT/A
30min-post-transfusion. Consistent with the in vitro toxin-
neutralization results, these human reticulocytes provided
protection against 10 LD50 BoNT/A in all recipient mice (Fig. 6e).
Since our hGPA-VNA/A-expressing human reticulocytes
showed similar morphology and vitality compared to its unmodi-
ﬁed in vitro-cultured human reticulocytes counterpart, we expected
that >90% of GPA-VNA/A cells would survive 1 day post-
transfusion in NOD/SCID mice and protect mice from a
low-dose challenge with BoNT/A. Indeed, when we transfused a
cohort of NOD/SCID recipient with 120,000,000 hGPA-VNA/A-
expressing human reticulocytes and challenged them 1 day post-
transfusion with 10 LD50 of BoNT/A, these mice were
protected (Fig. 6e).
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Fig. 4 RBCs expressing heterodimers of neutralizing VHHs are more protective than those expressing monomers. a Bispeciﬁc or monospeciﬁc antitoxin
proteins were engineered for expression on RBCs as GPA fusions. Chimeras were engineered to include the different protein segments as shown
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Discussion
Here we describe the production of genetically engineered RBCs
that carry cargoes of therapeutic value: in this case, VHHs that
neutralize a bacterial toxin and that have long circulatory half-life.
First, we demonstrated that VHHs fused to a GPA or Kell protein
can be functionally expressed on the surface of normal enucleated
mouse RBCs and human reticulocytes. These modiﬁcations of
RBCs do not materially affect their biogenesis, as judged by surface
protein expression, proliferation, cell size, and hemoglobin con-
tent. Second, these chimeric VHHs retain their potency in in vitro
BoNT/A-neutralization assays and in vivo toxin challenges.
Notably, mice transfused with RBCs expressing the GPA-VNA/A
chimera such that the engineered cells comprise <1% of the total
mouse RBCs survive a BoNT/A challenge of 10 LD50 BoNT/A for
up to 28 days. Third, we used a modiﬁed culture system and
genetically modiﬁed human CD34+ stem/progenitor RBCs to
produce enucleated human reticulocytes expressing the hGPA-
VNA/A chimera and showed that transfusion of these cells into
immune-compromised mice rendered them resistant to challenge
by a 10 LD50 dose of BoNT/A. Our RBC engineering method
should have widespread applications for prolonging half-life in the
circulation of any enzyme or anti-toxin used for prophylactic or
therapeutic treatments.
We previously reported sortase A-mediated modiﬁcation
(sortagging) to attach cargoes covalently to RBCs32. Sortase
A recognizes an LPXTG motif and cleaves the peptide bond
between the threonine and glycine residues to yield a thioester
acyl-enzyme intermediate. A nucleophile that contains suitably
exposed N-terminal glycines, (G)n, can resolve this intermediate,
covalently linking the two motifs via a peptide bond33. Despite
the ﬂexibility of cargo selection provided by sortase A-mediated
cargo delivery, human and mouse red cells contain only
~3,000–8,000 surface proteins with N- terminal (G)n motifs34,
which limits the cargo-loading numbers. The genetic engineering
method detailed in this report provides a way to bypass this
challenge, permitting greatly increased cargo capacity.
Compared with other RBC engineering methods, our methods
are better suited for long-term, persistent delivery of cargo.
For instance, RBC membrane-coating techniques produce
RBC-membrane-camouﬂaged polymeric nanoparticles by deriv-
ing membrane vesicles from RBCs and fusing these vesicles with
nanoparticles. This protocol enables the cargo to last ~50 h in
circulation35, while our genetically engineered mouse RBCs
circulate in the bloodstream for ~28 days. Covalent attachment of
cargo onto RBCs not only prolongs in vivo retention times
of chimeric proteins but also avoids their rapid clearance8.
Interestingly, we observed that the engineered RBCs that have
bound the antigen (toxin in our experiments) are cleared slightly
faster than are unperturbed engineered RBCs. It is not clear
whether this half-life difference is due to the large size of the
bound BoNT/A (150 kDa) or the binding of antigen itself; it
will be interesting to attach other VHHs, whose target antigens
differ in size and other properties, and determine the effects on
RBC clearance. Another possibility is that these toxin-carrying
RBCs are somehow seen by the cells of the reticuloendothelial
system as damaged RBCs and cleared by macrophages or
dendritic cells.
We showed that a single VHH (GPA-VHH7) is also able
to neutralize BoNT/A. Since each VHH comprises a single
immunoglobulin domain stabilized by one or two intramolecular
disulﬁde bonds that fold independently36, 37, it is likely possible
to engineer GPA or Kell chimeras that contain three or more
VHH domains and express these on the same RBCs. In this way,
one could engineer RBCs that bind multiple foreign toxins
or viruses and thus offer long-term prophylactic protection
against multiple pathogens.
Systemic administration of foreign proteins carries signiﬁcant
risk of inducing a strong antibody response. This is especially the
case for neutralizing antibodies derived from mice38. Such agents
usually require humanization at the expense of reducing afﬁnity and
speciﬁcity. In worst case scenarios, even with humanization, they
may prove too immunogenic to be administered more than
a handful of times39. Here we assessed whether long-term
protection against BoNT/A comes with a side effect immune
response by carrying out repeated transfusions of GPA-VNA/A
RBCs into a cohort of C57BL/6J recipients at days 1, 21, and 28. In
parallel, we also transfused unmodiﬁed RBCs or equimolar amounts
of recombinant VNA/A proteins with the same schedule. Multiple
transfusions of GPA-VNA/A RBCs were found to elicit an insig-
niﬁcant antibody response against intact VNA/A proteins,
comparable to mice receiving unmodiﬁed RBCs, whereas mice that
received VNA/A proteins developed a much higher titer of antibody
response against intact VNA/A proteins (Fig. 3d). This result
implies that the RBC vehicle, possibly by masking the VNA as the
RBC’s own proteins, can further minimize immune response
against the covalently attached VNA. Recently, we showed that red
cells with several different peptides covalently linked to their surface
do not induce an immune response to these peptides after trans-
fusion into a naive mouse. Rather, they induce tolerance to these
peptide antigens34. Therefore, GPA-VNA/A RBCs and other
engineered RBCs generated using similar methods can not only
provide long-term protection but may also permit multiple
administrations without provoking the immune system.
Based on previously reported culture systems using mobilized
human bone marrow CD34+ cells to produce RBCs, which yield
a lower number of cells26 and a lower percentage of enucleated
cells30, 31, 40, our six-stage culture system offers enhanced
enucleation. We increase the cell seeding density and reduce the
erythropoietin level during the last stage, suggesting that these two
factors positively affect reticulocyte production. Despite the higher
Table 1 Composition of the culture medium at each stage
Stage Expansion Diff1 Diff2 Diff3 Diff4 Diff5
Day D1–D5 D5–D9 D9–D12 D12–D16 D16–D20 D20–D23
Density 1E5/ml 1E5/ml Dilute into 4X 1E5/ml 1E6/ml 5E6/ml
Medium Stemspan IMDM IMDM IMDM IMDM IMDM
rhFLT3 Plasma Plasma Plasma Plasma Plasma
rhSCF AB serum AB serum AB serum AB serum AB serum
rhIL-3 Heparin Heparin Heparin Heparin Heparin
rhIL-6 Insulin Insulin Insulin Insulin Insulin
Dex Holo-transferrin Holo-transferrin Holo-transferrin Holo-transferrin Holo-transferrin
SCF SCF SCF Epo
IL-3 IL-3 Epo
Epo Epo
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percentage of enucleated cells, we have not investigated the
maturation status of the reticulocytes and cannot conclude that
these cells are fully mature red cells. Reduced enucleation is
observed in cells infected with lentiviruses, raising the safety
concern of transmission of genetic material. While one possible
solution is to ﬁlter nuclei and nucleated cells by leucocyte ﬁltration
as performed in other studies29, adjusting the transduction protocol
should be another possible method to reduce inﬂuence on culture
efﬁciency. On the other hand, there are several clinical trials of
cellular therapy using lentivirus-transduced cells that show great
safety41, 42. Improving vector designs to enable safe delivery should
be a consideration when engineering human RBCs in vitro.
Previous reports showed that the enucleated reticulocytes
produced in culture mature normally into biconcave mature
RBCs following transfusion into NOD/SCID mice, eliminating
the necessity of further in vitro maturation43. More importantly,
Giarratana et al.43 have shown that the half-life of in vitro-
cultured RBCs in the human body is ~26 days. If this half-life is
conﬁrmed in further studies, our engineered human reticulocytes
carrying BoNT/A VHHs, which are produced in vitro, should
provide effective long-term protection from lethal BoNT/A
challenges in humans.
Methods
Plasmids and generation of recombinant retroviruses and lentiviruses. Murine
stem cell virus (MSCV)-based retroviruses were produced and used to infect
erythroid progenitors following a previously described protocol44, and lentivirus
vectors used to infect human cells were also described previously45. The ciA-H7
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and ciA-B5 monomer sequences and the bispeciﬁc H7/B5 heterodimer sequence
were previously reported3 and the D10 and G10 sequences are unpublished
(but are available from Dr. Shoemaker). Human GPA and Kell cDNA sequences
were obtained from the National Center for Biotechnology Information, reference
sequences NM_002099.6 and NM_000420.2, respectively. These sequences were
used for synthesizing DNA fragments; these DNA fragments were cloned into
XhoI-cut XZ201 or HMD plasmids using a Gibson Assembly Kit. HMD vector uses
a HIV/MSCV hybrid long terminal repeat as the promoter. The XZ201 plasmid
was used for retrovirus production and the HMD plasmid was used for lentivirus
production. Both contain GFP inserted after an IRES sequence, which drives the
GFP expression.
293T cells were cultured in Dulbecco’s Modiﬁed Eagle Medium (DMEM) with
10% fetal bovine serum (FBS) in a humidiﬁed 5% CO2 atmosphere at 37 °C.
XZ201-based plasmids and pCLECO- or HMD-based plasmids and packaging
vectors, VSV-G and pD8.9, were incubated with medium and Fugene 6 according
to the Promega protocol. The mixture medium was changed after 6 h; retrovirus
and lentivirus were collected after 24 and 72 h for transfection, respectively.
Flow cytometric analyses and antibodies. All ﬂow cytometric data were
acquired on a ﬂuorescence-activated cell sorter (FACS) Fortessa ﬂow cytometer
(BD Biosciences) and analyzed using the Flowjo software (Tree Star). All stainings
were carried out in FACS buffer (2 mM EDTA and 5% FBS in phosphate-buffered
saline (PBS)) for 40 min at room temperature unless otherwise described. Samples
were washed twice with FACS buffer prior to ﬂow analyses. The following are
the antibodies used at 1:100 dilution: anti-human CD235A-APC (eBioscience,
17-9987042), anti-human CD71-FITC (eBioscience, 11-0719-42), anti-human
CD71-PeCy7 (Affymetrix, 25-0719-42), anti-human CD117-PeCy7 (eBioscience,
25-1178-42), anti-human CD117-BV605 (BioLegend, 313217), anti-human
CD49e-APC (BioLegend, 328012), anti-human CD29-PerCP-eFluor 710
(Affymetrix, 46-0299-41), anti-human CD49d-PE (Affymetrix, 12-0499-42),
anti-human CD240DCE-APC (Miltenyi Biotec, 130-104-818), anti-human
CD238-APC (Miltenyi Biotec, 130-104-951), anti-human CD47-PerCP-eFluor
710 (Affymetrix, 46-0479-42), anti-human CD147-PE(Affymetrix, 12-1472-42),
anti-human CD59-APC (Affymetrix, 17-0596-42), anti-myc tag-PE (Cell Signaling
Technology, 3739), anti-mouse Ter119-APC (eBioscience, 17-5921-83), and
anti-mouse CD71-PE (Affymetrix, 12-0711-83). Hoechst 33342 (Life Technologies,
H1399) was used to visualize nuclei.
Human CD34+ cell culture. Granulocyte-colony stimulating factor-mobilized
CD34+ peripheral blood stem cells (purchased from the Fred Hutchinson Cancer
Center) were thawed according to the vendor’s protocol. Cells were then placed
in expansion medium containing 100 ng/ml rhFLT3, 100 ng/ml recombinant
human stem cell factor (rhSCF), 20 ng/ml rhIL6, 20 ng/ml rhIL3, and 100 nM
dexamethasone in Stemspan II medium for 5 days at a density of 100,000 cells/ml.
The cells were then cultured in differentiation 1–2 medium (2% human
blood plasma, 3% human serum, 3 U/ml heparin, 10 μg/ml insulin, 200 μg/ml holo-
transferrin, 10 ng/ml rhSCF, 1 ng/ml interleukin-3, and 3 U/ml Epo in Iscove’s
Modiﬁed Dulbecco’s Medium (IMDM)) at a density of 100,000 cells/ml for 4 days
and at 200,000 cells/ml for 3 days. The medium was switched to Differentiation 3
medium (2% human blood plasma, 3% human serum, 3 U/ml heparin, 10 μg/ml
insulin, 200 μg/ml holo-transferrin, 10 ng/ml rhSCF, and 1 U/ml Epo in IMDM)
and the cell density was maintained at 100,000 cells/ml. After 4 days, the cells
were cultured at a density of 1,000,000 cells/ml in Differentiation 4 medium
(2% human blood plasma, 3% human serum, 3 U/ml heparin, 10 μg/ml insulin,
500 μg/ml holo-transferrin, and 0.1 U/ml Epo in IMDM) for an additional 4 days.
For culture stage 5, the medium was replaced by Differentiation 5 medium
(2% human blood plasma, 3% human serum, 3 U/ml heparin, 10 μg/ml
insulin, 500 μg/ml holo-transferrin in IMDM) and the density was increased to
5,000,000 cells/ml. Enucleated RBCs were ready to be used after 3 days.
Hemoglobin content measurement and histology stain of CD34+ cells. Cells
were stained on slides with May-Grünwald–Giemsa and diaminobenzidine
hydrochloride reagents (Sigma-Aldrich GS-500 and D-9015) for morphological
analyses. Hemoglobin content was measured at 540 nm wavelength light after
incubating one million cells with Drabkin’s reagent (RICCA Chemical Company,
2660-16). Human hemoglobin (Sigma-Aldrich H7379) was used for the standard
curve to calculate hemoglobin amounts from the O.D. 450 nm value.
Antibodies for western blotting to detect human CD34+ cell proteins.
Antibodies used were anti-XK(Thermo Fisher Scientiﬁc, PIPA540782), anti-EPB41
(Abcam, ab54597), anti-MPP1 (Abcam, ab96255), anti-CD47 (Abcam, ab3283),
anti-band 3 (Santa Cruz Biotechnology, sc-133190), anti-Integrin β1 (Santa Cruz
Biotechnology, sc-18887), anti-Glycophorin C (Santa Cruz Biotechnology,
sc-59183), anti-GPA (Santa Cruz Biotechnology, sc-59182), and anti-Kell
(Santa Cruz Biotechnology, sc-271070). All antibodies were used at 1:1,000
dilution. Original images of western blottings presented in the manuscript are
shown in Supplementary Fig. 5.
Calculation of the number of recombinant proteins on murine RBCs. Western
blottings were performed with anti-myc-Tag (9B11) mouse monoclonal antibody
(Cell Signaling no. 2040, 1:1,000 dilution). In all, 10, 50, and 100 ng myc proteins
were used as a quantiﬁcation standard. To calculate the number of recombinant
proteins per cell, a linear plot was generated from the reference myc signal
intensities and the number of chimeric RBC proteins expressed per RBC was then
derived from the plot. As determined by the myc signal intensity in the western
blotting with an anti-myc antibody and as quantiﬁed by ImageJ, 1,000,000 murine
GPA-VNA/A cells contained 500 ng GPA-VNA/A proteins. The molecular weight
of GPA-VNA/A is 60,000. Using Avogadro’s number, calculation shows that each
red cell expresses 4,600,000 GPA-VNA/A proteins. Similarly, 1,000,000 Kell-VNA/
A cells contained 400 ng Kell-VNA/A proteins, of molecular weight 110 kD. Again
using Avogadro’s number, calculation shows that each red cell expresses 2,190,000
Kell-VNA/A proteins.
Isolation of erythroid progenitors from murine fetal liver cells. Enriched
erythroid progenitors were puriﬁed from E14.5 C57BL/6J mouse embryos and
cultured in vitro for erythroid differentiation following a protocol described in
detail previously32. Brieﬂy, pregnant C57BL/6J mice at embryonic day 14.5 were
killed by CO2 asphyxiation and the embryos were collected. The fetal livers were
isolated and suspended in PBS with 2% FBS and 100 μM EDTA. Mature RBCs in
the cell suspension were lysed by incubation for 10 min with an ammonium
chloride solution (Stemcell). Following the manufacturer’s protocol, lineage-
negative cells were obtained after magnetic depletion of lineage-positive cells using
the BD Pharmingen Biotin MouseLineage Panel (559971; BD Biosciences) and BD
Streptavidin Particles Plus-DM (557812; BD Biosciences). These lineage-negative
fetal liver cells were enriched >90% for erythroid progenitors.
Viral infection and culture of murine erythroid progenitors. MSCV-based
retroviruses were produced and used to infect erythroid progenitors following a
previously described protocol44. Brieﬂy, after isolation, lineage-negative fetal liver
cells were plated in 24-well plates at 100,000 cells per well, covered by 1 ml virus
containing supernatant, and centrifuged at 500 g for 90 min at 30 °C. After this
spin-infection, the virus supernatant was replaced with erythroid maintenance
medium (StemSpan-SFEM; StemCell Technologies) supplemented with 100 ng/ml
recombinant mouse SCF (R&D Systems), 40 ng/ml recombinant mouse IGF1
(R&D Systems), 100 nM dexamethasone (Sigma), and 2 U/ml erythropoietin
(Amgen) and cultured at 37 °C. GFP+ cells were sorted by ﬂow cytometry after 16 h
and cultured for another 48 h in erythroid differentiation medium (IMDM
containing 15% (vol/vol) FBS (Stemcell), 1% detoxiﬁed bovine serum albumin
(BSA; Stemcell), 500 μg/ml holo-transferrin (Sigma-Aldrich), 0.5 U/ml Epoetin
(Epo; Amgen), 10 μg/ml recombinant human insulin (Sigma-Aldrich), and 2 mM
L-glutamine (Invitrogen)) at 37 °C.
Transplantation of mouse fetal liver cells. C57BL/6J (Jackson Laboratory) or
CD-1 (Charles River) mice were subjected to lethal irradiation of 1050 rad carried
out in a Gammacell 40 irradiator chamber (Nordion International Inc.) 1 day
before transplantation. A total of 1,500,000 virally infected murine erythroid
progenitors from mouse fetal liver cultured in erythroid maintenance medium,
produced as described in the previous paragraph, were harvested and resuspended
in 100 μl PBS32. These cells were then injected retro-orbitally into an irradiated
mouse. Mice were bled for examining chimeric protein expression and further
analysis 5 weeks after transplantation. Mice were bled at the indicated time points
for performing CBC analysis on a SIEMENS ADVIA 2120i machine.
Transfusion and in vivo survival of GPA-VNA RBCs. A total of 200 μl blood
from transplanted mice containing RBCs expressing the GPA-VNA chimera was
collected into heparinized tubes (Fisher Scientiﬁc, 365965). RBCs were washed
twice in PBS and resuspended in PBS. Labeling was then carried out with 5 μM
CellTrace violet dye for 20 min at room temperature (Life Technologies).
FBS (10%) in PBS was then added to RBCs for quenching the staining reaction.
Violet-labeled RBCs were washed twice with PBS and resuspended in 200 μl sterile
PBS for intravenous injection into recipient mice. An equal volume of unmodiﬁed
RBCs, similarly stained, served as a control.
A drop of blood, ~20 μl, was collected into heparinized tubes by retro-orbital
bleeding 1 h after transfusion at day 0 and every 3–4 days for 1 month as indicated
in the text. These blood samples were washed once with FACS buffer and then
subjected to staining with anti-Ter119-APC and anti-myc tag-PE for 30 min on ice.
Samples were washed twice with FACS buffer prior to analyses on a FACS Fortessa
ﬂow cytometer for violet ﬂuorescence and for GFP, Ter119, and myc signals.
ciBoNT/A ﬂow cytometry and ELISA assays for toxin binding to RBCs and
quantifying toxin in serum. In all, 200 μl blood from transplanted mice that
contain RBCs expressing the GPA-VNA chimera was collected into heparinized
tubes and stained with CellTrace violet dye as described above (Figs 3a–c). After
resuspending the violet-stained RBCs in 200 μl PBS, RBCs were further incubated
with 1 μg catalytically inactive recombinant BoNT/A (ciBoNT/A) on ice for 40 min
prior to intravenous injection into recipient mice. An equal volume of unmodiﬁed
RBCs, also stained and incubated with ciBoNT/A, served as a control. One drop of
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blood was collected into heparinized tubes by retro-orbital bleeding 1 h after
transfusion (termed day 0) and every 3–4 days for 14 days as indicated in the
text and ﬁgure legend. Samples were washed once with FACS buffer and then
subjected to staining with anti-myc tag-PE to detect surface-expressed VNAs and
anti-S-tag-APC (VWR, 10065-802) to indirectly detect ciBoNTA by incubation
with the bispeciﬁc BoNT/A-binding heterodimer, ciA-F12/D123, which carries
the S-tag. Samples were washed twice with FACS buffer prior to analyses on a
FACS Fortessa ﬂow cytometer for violet ﬂuorescence, GFP, and S-tag (indicating
toxin that is bound to the RBC surface) signals.
In a parallel experiment to measure ciBoNT/A in serum of transfused mice
(Fig. 3a), 200 μl blood from transplanted mice that contain RBCs expressing the
GPA-VNA chimera was also collected into heparinized tubes. RBCs were washed
twice in PBS and resuspended in PBS to a volume of 200 μl. As above, these RBCs
were incubated with 2 ng ciBoNT/A on ice for 40 min prior to intravenous
injection into recipient mice. The recipient mice were then bled 1 h after
transfusion (day 0) and every week for 1 month as indicated in the text. In all,
100 μl blood was collected into a serum separator tube (Fisher Scientiﬁc,
02675185), and blood samples were allowed to clot at room temperature for
15–30 min. Serum and clots were then separated by centrifugation at 10,000 g for
10 min at 4 °C.
ELISA plates coated with polyclonal anti-BoNT/A (Metabiologics, Inc.) were
blocked with blocking buffer (0.05% Tween20 + 2% BSA in PBS) for 2 h at room
temperature prior to addition of 10 μl serum samples in 90 μl PBS; the incubation
period was 3.5 h at room temperature, followed by four washes with PBS. Plates
were then incubated with VHH ciA-D123 against BoNT/A, which carries an E-tag,
and anti-E tag-horseradish peroxidase (HRP; Bethyl Laboratories, A190-133P),
both at 1:1,000 dilutions in blocking buffer for 1 h. Plates were then washed again
four times with PBS and developed with 3,3′,5,5′-Tetramethylbenzidine (TMB)
liquid substrate reagent (Sigma). Reactions were stopped with 1 N HCl and read at
450-nm absorbance. As a quantiﬁcation standard, we used serially diluted 1 μg
catalytically inactive recombinant BoNT/A.
ELISA for detecting antibody responses against VNA/A. Freshly bled 200 μl
GPA-VNA/A RBCs and WT C57BL/6J RBCs were washed once with DMEM
medium, twice in PBS, and resuspended in sterile PBS to make 200 μl ﬁnal volume
for intravenous injection into C57BL/6J recipient mice. We also transfused a
separate cohort of C57BL/6J recipient mice with equimolar amounts of
recombinant VNA/A in 200 μl PBS. Three and 4 weeks later, second and third
transfusions were carried out in a similar fashion, using the same cohort of reci-
pient mice. Serum samples were collected from these mice 5 days after the last
transfusion. Ninety-six-well plates were coated with 10 μg/ml recombinant VNA/A
in PBS overnight at 4 °C and blocked in blocking buffer (10% heat inactivated FBS
in PBS) prior to addition of 5 μl serum samples in 180 μl blocking buffer.
Incubation with test serum was for 3 h at room temperature. Plates were washed
four times with PBS, incubated with goat anti-mouse immunoglobulin G–HRP
(Southern Biotech) at 1:10,000 in blocking buffer for 1 h, and developed with TMB
liquid substrate reagent (Sigma). The reaction was stopped with 1 N HCl and
absorbance was read at 450 nm.
Neuron culture and BoNT/A neutralization assay. We followed a previously
described protocol3. In brief, rat (Sprague Dawley strain) cortical neurons were
prepared from E18 to E19 embryos. Dissected cortices were dissociated with papain
following the manufacturer’s instructions (Worthington Biochemical, Lakewood,
NJ, USA), and cells were plated on poly-D-lysine coated 24-well plates at 250,000
cells per well in 1 ml Neurobasal medium (Thermo Fisher, Cat. No. 21103-049)
supplemented with 2% B27 (Thermo Fisher, Cat. No. 17504-001) and Glutamax
(Thermo Fisher, Cat. No. 35050-061). Experiments were carried out using DIV
(days in vitro) 11 neurons.
RBCs were pelleted (500 g, 5 min) and resuspended in conditioned neuron
culture medium taken from neuron culture plates (0.5 ml per well), and 20 pM
BoNT/A was added. The mixture of RBCs and BoNT/A was incubated at 37 °C for
30 min and then added to the original well containing the cultured neurons.
Neurons were cultured further for 9 h. Neuron lysates were then collected in 100 µl
RIPA buffer (50 mM Tris, 1% NP40, 150 mM NaCl, 0.1% sodium dodecyl sulfate
(SDS), plus a protease inhibitor cocktail (Millipore)). Lysates were centrifuged for
10 min at 20,000 g at 4 °C. Supernatants were subjected to SDS–polyacrylamide gel
electrophoresis and immunoblot analysis using an SNAP25 antibody46 and the
enhanced chemiluminescence method47.
Mouse survival assay. Our mouse studies were conducted under animal protocols
approved by the Division of Comparative Medicine at MIT or the Tufts University
IACUC. Eight-week-old female CD-1, C57BL/6J, or NOD/SCID (Jackson
Laboratory) mice were weighed before toxin injection and blood transfusion. The
average weight of the mice was used to calculate the lethal dose of BoNT/A toxin
(Metabiologics, Inc.); the LD50 of BoNT/A we employed for C57BL/6J was 1.5 pg/g,
which was measured under our animal protocol. The LD50 of BoNT/A for CD-1
mice is 1.86 pg/g. The LD50 of BoNT/B is 1.58 pg/g. When co-administered
with toxin, wild-type or engineered RBCs were transfused in a 200 μl PBS solution
retro-orbitally (C57BL/6J mice) or intravenously (CD-1 mice) 30 min–2 h prior to
administration of BoNT/A. Mice were observed 2–6 times/day for 7 days. Mice
with symptoms such as difﬁculty moving, open-mouth breathing, and wasp like
narrow waist were killed and scored as moribund.
Transfusion and in vivo survival of in vitro-differentiated human reticulo-
cytes. At day 23, in vitro-differentiated human reticulocytes were collected,
counted, washed once in PBS, and resuspended in PBS. Labeling of these human
reticulocytes was carried out using 5 μM carboxyﬂuorescein succinimidyl ester
(CFSE) according to the manufacturer’s instructions (Life Technologies). FBS
(10%) in PBS was then added to the reticulocytes for quenching the staining
reaction. CFSE-labeled reticulocytes were then washed twice with PBS and
resuspended in 200 μl sterile PBS for intravenous injection into NOD/SCID mice
at 250,000,000 reticulocytes per mouse. These recipient mice had been intraper-
itoneally injected with 100 and 50 μl clodronate liposomes at 3 days and 1 day prior
to transfusion, respectively. A drop of blood, ~20 μl, was collected into heparinized
tubes by retro-orbital bleeding for 1 week starting at 1 h after transfusion at day 0
and at ﬁve more time points as indicated in the text. These blood samples were
washed once with FACS buffer and then subjected to staining with anti-CD235A-
APC for 30 min on ice. Samples were washed twice with FACS buffer prior to
analyses on a FACS Fortessa ﬂow cytometer for CFSE and CD235A signals.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request
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